Epstein-Barr virus-associated B-cell non-Hodgkin lymphoma following treatment of hairy cell leukemia with cladribine [3]

Blood

Volumn 102, Issue 9, 2003, Pages 3457-3458

  Lenz, Georg ^a   Golf, Alexander ^b   Rüdiger, Thomas ^b   Hiddemann, Wolfgang ^b   Haferlach, Torsten ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; CIDOFOVIR; CLADRIBINE; EPSTEIN BARR VIRUS ANTIGEN; LATENT MEMBRANE PROTEIN 1; MONOCLONAL ANTIBODY; RITUXIMAB; VIRUS DNA; VORICONAZOLE;

ADULT; ASPERGILLOSIS; B CELL LYMPHOMA; BONE MARROW BIOPSY; CANCER RISK; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; HAIRY CELL LEUKEMIA; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; INFECTION; LETTER; LEUKEMIA; LYMPH NODE BIOPSY; MALE; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; SECOND CANCER;

EID: 0142152419     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-07-2494     Document Type: Letter

References (4)

1. Au WY, Klasa RJ, Gallagher R, Le N, Gascoyne RD, Connors JM. Second malignancies in patients with hairy cell leukemia in British Columbia: a 20-year experience. Blood. 1998;92:1160-1164.
2. Goodman GR, Burian C, Koziol JA, Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol. 2003;21: 891-896.
3. Milpied N, Vasseur B, Parquet N, et al. Humanized anti-CD20 monoclonal antibody (Rituximab) in post-transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol. 2000;11:113-116.
4. Kelaidi C, Tulliez M, Lecoq-Lafon C, et al. Long-term remission of an EBV-positive B cell lymphoproliferative disorder associated with rheumatoid arthritis under methotrexate with anti-CD20 monoclonal antibody (Rituximab) monotherapy. Leukemia. 2002;16:2173-2174.